Raymond James Analysts Give Knight Therapeutics (TSE:GUD) a C$10.25 Price Target

Share on StockTwits

Raymond James set a C$10.25 target price on Knight Therapeutics (TSE:GUD) in a research note published on Monday morning, BayStreet.CA reports. The brokerage currently has an outperform rating on the stock.

A number of other brokerages also recently commented on GUD. Bloom Burton downgraded Knight Therapeutics from a buy rating to an accumulate rating in a research report on Monday, June 29th. National Bank Financial decreased their price target on Knight Therapeutics from C$8.75 to C$8.25 and set an outperform rating for the company in a research report on Monday, June 29th.

Shares of Knight Therapeutics stock opened at C$6.65 on Monday. The company has a market cap of $896.93 million and a PE ratio of 133.00. Knight Therapeutics has a 52 week low of C$4.73 and a 52 week high of C$8.88. The business has a 50 day moving average price of C$6.86 and a 200-day moving average price of C$7.03. The company has a quick ratio of 1.74, a current ratio of 2.07 and a debt-to-equity ratio of 7.38.

Knight Therapeutics (TSE:GUD) last issued its quarterly earnings data on Friday, June 26th. The company reported C$0.05 EPS for the quarter, topping the consensus estimate of C($0.08) by C$0.13. The company had revenue of C$45.84 million during the quarter, compared to analysts’ expectations of C$60.35 million. As a group, research analysts anticipate that Knight Therapeutics will post 0.11 EPS for the current year.

Knight Therapeutics Company Profile

Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.

Featured Article: Moving Average Convergence Divergence (MACD)

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply